Insmed Incorporated (NASDAQ:INSM) Shares Sold by Granahan Investment Management LLC

Granahan Investment Management LLC reduced its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 3.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,354 shares of the biopharmaceutical company's stock after selling 7,991 shares during the period. Granahan Investment Management LLC owned approximately 0.12% of Insmed worth $14,454,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in INSM. Principal Financial Group Inc. boosted its holdings in shares of Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock worth $136,648,000 after purchasing an additional 214,130 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in shares of Insmed by 237.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company's stock worth $4,115,000 after purchasing an additional 41,918 shares during the period. JCIC Asset Management Inc. boosted its holdings in shares of Insmed by 40.7% during the fourth quarter. JCIC Asset Management Inc. now owns 2,560 shares of the biopharmaceutical company's stock worth $177,000 after purchasing an additional 740 shares during the period. Capital CS Group LLC bought a new position in Insmed in the fourth quarter worth about $586,000. Finally, Park Avenue Securities LLC raised its stake in Insmed by 42.1% in the fourth quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company's stock worth $549,000 after buying an additional 2,358 shares in the last quarter.

Insmed Stock Down 1.2%

Shares of INSM traded down $0.83 during mid-day trading on Tuesday, hitting $66.92. The company's stock had a trading volume of 238,518 shares, compared to its average volume of 2,316,984. The company's 50-day moving average is $72.17 and its 200-day moving average is $73.26. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The firm has a market capitalization of $12.17 billion, a price-to-earnings ratio of -12.04 and a beta of 0.84. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. During the same period in the previous year, the company earned ($1.06) EPS. The company's revenue was up 22.9% on a year-over-year basis. On average, equities research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Insmed in a research note on Tuesday. They issued a "buy" rating and a $105.00 price target for the company. Wells Fargo & Company increased their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. Truist Financial raised their target price on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $94.63.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 6,830 shares of the firm's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $72.57, for a total transaction of $495,653.10. Following the sale, the chief executive officer now owns 233,924 shares in the company, valued at approximately $16,975,864.68. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the sale, the chief financial officer now owns 118,863 shares in the company, valued at approximately $9,545,887.53. This represents a 13.36% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 88,232 shares of company stock worth $6,868,473. 3.00% of the stock is owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.